Precipio operates two complementary divisions. A Pathology Services Division delivers cancer diagnostic testing from CLIA-certified facilities in New Haven and Omaha, generating recurring revenue. A Products Division develops proprietary assays for clinical laboratories, drawing on the lab’s infrastructure, samples, and physician relationships to accelerate development.

Cancer misdiagnosis is a persistent and costly issue in U.S. healthcare. Blood cancer misdiagnosis rates have been reported as high as 28%, and molecular turnaround times can run 10 to 15 days. The American Medical Association has estimated that diagnostic errors cost the U.S. healthcare system more than $100 billion annually.

Precipio’s portfolio is anchored by three products. HemeScreen is a targeted molecular panel platform for hematologic disease. IV-Cell is a universal cell culture media that enables simultaneous culturing of all four hematopoietic lineages. The Bloodhound BCR-ABL1 assay was recently the subject of a joint publication with Memorial Sloan Kettering Cancer Center.

Precipio reaches the U.S. clinical laboratory market through distribution agreements with McKesson, Fisher Healthcare, Cardinal Health, and Medline. These partners cover physician-owned laboratories, hospital and academic centers, and reference labs, giving Precipio market reach without the cost of a large direct sales organization.

Because Precipio is the first commercial user of every product it develops, the company validates and refines assays inside its own laboratory before launch. The company has cited internal examples of new assays developed in roughly three months for under $100,000, a fraction of the time and capital typically required by standalone diagnostics developers.

Precipio’s initial focus is the blood cancer genetics market, but the underlying platform is designed to extend into broader cancer and molecular diagnostics. By building credibility, distribution, and an installed base in hematology first, Precipio is positioning itself to apply the same integrated lab-and-product model to adjacent diagnostic categories.